NCT02547233View on ClinicalTrials.gov

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

PHASE3CompletedINTERVENTIONAL
Enrollment

437

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2017

Conditions
Actinic Keratosis
Interventions
DRUG

LEO 43204 gel

DRUG

Vehicle gel

Trial Locations (1)

60005

Altman Dermatology Associates, Arlington Heights

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY